AnaptysBio (NASDAQ:ANAB) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $66.00 target price on the biotechnology company’s stock.

A number of other analysts also recently issued reports on the stock. Wedbush increased their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Barclays upped their price objective on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 4th. Truist Financial raised shares of AnaptysBio to a “hold” rating in a research note on Wednesday, March 25th. Finally, Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.44.

AnaptysBio Trading Down 3.5%

Shares of ANAB stock opened at $55.39 on Monday. AnaptysBio has a twelve month low of $15.40 and a twelve month high of $68.39. The stock has a market cap of $1.59 billion, a P/E ratio of -106.52 and a beta of 0.32. The stock has a 50 day moving average of $55.49 and a 200 day moving average of $44.01.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.89 by $0.69. The business had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, research analysts predict that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has approved a share buyback plan on Friday, March 27th that allows the company to repurchase $100,000.00 billion in shares. This repurchase authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at AnaptysBio

In related news, insider Eric J. Loumeau sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total transaction of $540,000.00. Following the transaction, the insider directly owned 12,835 shares in the company, valued at approximately $693,090. The trade was a 43.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Magda Marquet sold 11,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the sale, the director directly owned 9,930 shares of the company’s stock, valued at approximately $478,923.90. This represents a 52.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 110,193 shares of company stock valued at $5,333,138. Company insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC raised its holdings in AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the period. Larson Financial Group LLC increased its position in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the last quarter. Bessemer Group Inc. increased its position in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. lifted its holdings in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,326 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.